SLFN11 Expression and Efficacy of PARP Inhibitor Therapy in Extensive Stage Small Cell Lung Cancer: ECOG-ACRIN 2511 Study

被引：0
|
作者：
Owonikoko, T. [1 ]
Dahlberg, S. [2 ]
Sica, G. [3 ]
Poirier, J. [4 ]
Byers, L. [5 ]
Rudin, C. [6 ]
Wistuba, I. [7 ]
Ramalingam, S. [8 ]
机构：
[1] Emory Univ, Hematol Med Oncol, Atlanta, GA 30322 USA
[2] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA
[3] Emory Univ, Pathol, Atlanta, GA 30322 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] UT MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
[6] Mem Sloan Kettering, New York, NY USA
[7] Univ Texas MD Anderson Canc Ctr, Translat Mol Pathol, Houston, TX 77030 USA
[8] Emory Univ, Winship Canc Inst, Med Oncol, Atlanta, GA 30322 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
small cell lung cancer; biomarker; SLFN11;
D O I：
10.1016/j.jtho.2018.08.1829
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.12-06
引用
收藏
页码：S972 / S972
页数：1
相关论文
共 50 条
  • [21] Loss of SLFN11 or gain of TWIST1 promote chemotherapy resistance in small cell lung cancer
    Gardner, Eric E.
    Lok, Benjamin H.
    Schneeberger, Valentina E.
    de Stanchina, Elisa
    Poirier, John T.
    Rudin, Charles M.
    CANCER RESEARCH, 2016, 76
  • [22] Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    Liang, Fei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 259 - +
  • [23] The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer
    Scattolin, Daniela
    Dal Maso, Alessandro
    Ferro, Alessandra
    Frega, Stefano
    Bonanno, Laura
    Guarneri, Valentina
    Pasello, Giulia
    CANCER TREATMENT REVIEWS, 2024, 128
  • [24] Radiation Therapy in extensive Stage Small Cell Lung Cancer
    Jeremic, Branislav
    Gomez-Caamano, Antonio
    Dubinsky, Pavol
    Cihoric, Nikola
    Casas, Franesc
    Filipovic, Nenad
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [25] Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet! Reply
    Pietanza, M. Catherine
    Diao, Lixia
    Wang, Jing
    Byers, Lauren A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03)
  • [26] Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
    Leal, Ticiana
    Wang, Yating
    Dowlati, Afshin
    Lewis, DeQuincy Andrew
    Chen, Yuanbin
    Mohindra, Amit Ramesh
    Razaq, Mohammad
    Ahuja, Harish G.
    Liu, Jijun
    King, David M.
    Sumey, Christopher Joseph
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer
    Kundu, Kiran
    Cardnell, Robert J.
    Zhang, Bingnan
    Shen, Li
    Stewart, C. Allison
    Ramkumar, Kavya
    Cargill, Kasey R.
    Wang, Jing
    Gay, Carl M.
    Byers, Lauren A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (11) : 4095 - +
  • [28] FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11
    Yan-ping Yin
    Li-ying Ma
    Guo-zhen Cao
    Jing-han Hua
    Xiao-tong Lv
    Wen-chu Lin
    Acta Pharmacologica Sinica, 2022, 43 : 2119 - 2127
  • [29] FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11
    Yin, Yan-ping
    Ma, Li-ying
    Cao, Guo-zhen
    Hua, Jing-han
    Lv, Xiao-tong
    Lin, Wen-chu
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (08) : 2119 - 2127
  • [30] SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab plus talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)
    Abdel Karim, Nagla Fawzy
    Miao, Jieling
    Reckamp, Karen L.
    Michael Gay, Carl
    Averett Byers, Lauren
    Zhao, Yingqi
    Weber Redman, Mary
    Carrizosa, Daniel R.
    Wang, Wei-Lien
    Petty, William J.
    Mehta, Kathan
    Faller, Bryan A.
    Agamah, Edem S.
    Kasbari, Samer S.
    Katipamula Malisetti, Rajini
    Kumar, Atul
    Schallenkamp, John
    Chaitanya Alluri, Krishna
    Elaine Gray, Jhanelle
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345